Drug intelligence / Profile preview

CTI-005

Development stage: Preclinical
Lead developer: Cellics Therapeutics
Modality: Nanoparticles → Drug Delivery Systems

Overview

**CTI-005** is an investigational red blood cell nanosponge therapeutic being developed by Cellics Therapeutics for **methicillin-resistant *Staphylococcus aureus* pneumonia**. It is a **biologic nanoparticle** built using the company's cellular nanoparticle technology, in which engineered red blood cell membrane-derived nanosponges act as decoys that **absorb and neutralize pore-forming bacterial toxins** rather than directly killing bacteria. Based on the provided context, CTI-005 is intended as a **bacterial toxin inhibitor** for severe infectious disease, and it has reportedly received **IND clearance** for clinical development.

Other names: Red Blood Cell Nanosponge

Targets

Staphylococcus aureus pore-forming toxins

Beyond the preview

Go deeper on CTI-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTI-005.

Explore the full profile